&lt;p&gt;MicroRNA-193a-3p suppresses the colorectal cancer cell proliferation and progression through downregulating the PLAU expression&lt;/p&gt;

Lin, Mao‐Song; Zhang, Zan; Gao, Mingjun; Yu, Hong; Sheng, Haihui; Huang, Junxing

doi:10.2147/cmar.s208233

Cited by 54 publications

(36 citation statements)

References 39 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PLAU upregulation in primary tumor tissues is positively correlated with distant metastasis and indicates poor patient prognosis in CRC [ 30 ]. MiR-193a inhibits CRC cell growth and progression partly by downregulating the expression of target gene PLAU, which is consistent with our prediction of PLAU/miR-193a interaction [ 31 ]. VCAN is overexpressed in various human malignancies, including CRC [ 32 – 37 ], and CRC patients with high VCAN expression have worse disease outcomes than those with lower expression [ 38 ].…”

Section: Discussionsupporting

confidence: 91%

Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer

Chen

Song

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background Competing endogenous RNA (ceRNA) represents a class of RNAs (e.g., long noncoding RNAs [lncRNAs]) with microRNA (miRNA) binding sites, which can competitively bind miRNA and inhibit its regulation of target genes. Increasing evidence has underscored the involvement of dysregulated ceRNA networks in the occurrence and progression of colorectal cancer (CRC). The purpose of this study was to construct a ceRNA network related to the prognosis of CRC and further explore the potential mechanisms that affect this prognosis. Methods RNA-Seq and miRNA-Seq data from The Cancer Genome Atlas (TCGA) were used to identify differentially expressed lncRNAs (DElncRNAs), microRNAs (DEmiRNAs), and mRNAs (DEmRNAs), and a prognosis-related ceRNA network was constructed based on DElncRNA survival analysis. Subsequently, pathway enrichment, Pearson correlation, and Gene Set Enrichment Analysis (GSEA) were performed to determine the function of the genes in the ceRNA network. Gene Expression Profiling Interactive Analysis (GEPIA) and immunohistochemistry (IHC) were also used to validate differential gene expression. Finally, the correlation between lncRNA and immune cell infiltration in the tumor microenvironment was evaluated based on the CIBERSORT algorithm. Results A prognostic ceRNA network was constructed with eleven key survival-related DElncRNAs (MIR4435-2HG, NKILA, AFAP1-AS1, ELFN1-AS1, AC005520.2, AC245884.8, AL354836.1, AL355987.4, AL591845.1, LINC02038, and AC104823.1), 54 DEmiRNAs, and 308 DEmRNAs. The MIR4435-2HG- and ELFN1-AS1-associated ceRNA subnetworks affected and regulated the expression of the COL5A2, LOX, OSBPL3, PLAU, VCAN, SRM, and E2F1 target genes and were found to be related to prognosis and tumor-infiltrating immune cell types. Conclusions MIR4435-2HG and ELFN1-AS1 are associated with prognosis and tumor-infiltrating immune cell types and could represent potential prognostic biomarkers or therapeutic targets in colorectal carcinoma.

show abstract

Section: Discussionsupporting

confidence: 91%

Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer

Chen

Song

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Some studies report that the expression level of PLAU is significantly correlated to tumor cell lymph node and distant organ metastasis ( Gutierrez et al, 2000 ). Emerging evidence implies that PLAU plays a critical role in the initiation and development of various cancers including breast cancer, colorectal cancer, and esophageal cancer ( Li et al, 2017 ; Lin et al, 2019 ; Novak et al, 2019 ). However, the role of PLAU needs to be explored further in HNSCC.…”

Section: Introductionmentioning

confidence: 99%

Overexpressed PLAU and its potential prognostic value in head and neck squamous cell carcinoma

Chen

Wang

et al. 2021

PeerJ

View full text Add to dashboard Cite

Background Metastasis is a major event for survival and prognosis in patients with head and neck squamous cell carcinomas (HNSCC). A primary cause of metastasis is the proteolytic degradation of the extracellular matrix (ECM). The plasminogen activator urokinase (PLAU) is involved in the transformation of plasminogen to plasmin leading to hydrolyzation of ECM-related proteins. However, the role of PLAU expression in HNSCC is unclear and the worth being investigated. Methods PLAU expression profiles and clinical parameters from multiple HNSCC datasets were used to investigate the relationship of PLAU expression and HNSCC survival. GO and PPI network were established on PLAU-related downstream molecular. The stroma score was deconvoluted for analysis of PLAU’s association with the immune environment. ROC analysis was applied to show the performance of PLAU in predicting HNSCC prognosis. Results PLAU mRNA was significantly elevated, as opposed to its methylation, in HNSCC tumor samples over normal specimens (all p < 0.01). Univariate and multivariate cox analysis showed PLAU could be an independent indicator for HNSCC prognosis. Combining with neck lymph node status, the AUC of PLAU in predicting 5-years overall survival reached to 0.862. GO enrichment analysis showed the major biological process (extracellular matrix organization and the P13K-Akt signaling pathway) may involve to the possible mechanism of PLAU’s function on HNSCC prognosis. Furthermore, PLAU expression was positively correlated with stroma cell score, M1 type macrophages, and negatively associated with CD4 + T cell, Tregs cell, and follicular helper T cell. Conclusions PLAU might be an independent biomarker for predicting outcomes of HNSCC patients. The elevated expression of PLAU was associated with HPV positivity and neck node status. The PI3K-Akt pathway and aberrant proportions of immune cells might underly the mechanism of PLAU’s oncogene role in HNSCC.

show abstract

“…All of the genes in the IGBRS were found to be involved in CRC progression ( Kalmár et al, 2015 ; Mar et al, 2015 ; D’Eliseo et al, 2016 ; Morgan et al, 2018 ; Zhou et al, 2018 ; Liao et al, 2019 ; Lin et al, 2019 ). Bone morphogenetic protein 4 ( BMP4 ) encodes a secreted ligand of the transforming growth factor-beta (TGF-β) superfamily of proteins.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of a Novel Tumor Progression-Associated Immune Signature in Colorectal Adenocarcinoma

Mao

Yang

Zheng

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

BackgroundSome colorectal adenocarcinoma (CRC) patients are susceptible to recurrence, and they rapidly progress to advanced cancer stages and have a poor prognosis. There is an urgent need for efficient screening criteria to identify patients who tend to relapse in order to treat them earlier and more systematically.MethodsWe identified two groups of patients with significantly different outcomes by unsupervised cluster analysis of GSE39582 based on 101 significantly differentially expressed immune genes. To develop an accurate and specific signature based on immune-related genes to predict the recurrence of CRC, a multivariate Cox risk regression model was constructed with a training cohort composed of 519 CRC samples. The model was then validated using 129, 292, and 446 samples in the real-time quantitative reverse transcription PCR (qRT-PCR), test, and validation cohorts, respectively.ResultsThis classification system can also be used to predict the prognosis in clinical subgroups and patients with different mutation states. Four independent datasets, including qRT-PCR and The Cancer Genome Atlas (TCGA), demonstrated that they can also be used to accurately predict the overall survival of CRC patients. Further analysis suggested that high-risk patients were characterized by worse effects of chemotherapy and immunotherapy, as well as lower immune scores. Ultimately, the signature was identified as an independent prognostic factor.ConclusionThe signature can accurately predict recurrence and overall survival in patients with CRC and may serve as a powerful prognostic tool to further optimize cancer immunotherapy.

show abstract

<p>MicroRNA-193a-3p suppresses the colorectal cancer cell proliferation and progression through downregulating the PLAU expression</p>

Cited by 54 publications

References 39 publications

Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer

Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer

Overexpressed PLAU and its potential prognostic value in head and neck squamous cell carcinoma

Clinical Significance of a Novel Tumor Progression-Associated Immune Signature in Colorectal Adenocarcinoma

Contact Info

Product

Resources

About